Victor Golmer
Makers of copycat versions of Novo Nordisk’s (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing the FDA for removing the GLP-1 medication from its shortage list.
The Outsourcing Facilities Association, which represents drug compounders, filed the suit
